In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Short and medium-term safety and tolerability of Sacubitril-Valsartan and Empaglifozin joint intake

Session Poster Session 2

Speaker Herminio Morillas Climent

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : HMC Herminio Morillas Climent (Alicante,ES), JSM Julia Seller Moya (Alicante,ES), EGJ Emilio Galcera Jornet (Alicante,ES), EAT Edgardo Alania Torres (Alicante,ES), AVL Alvaro Vicedo Lopez (Alicante,ES), YRP Ydelise Rodriguez Pichardo (Alicante,ES), AL Ainhoa Larumbe (Alicante,ES), AVM Alfonso Valle Munoz (Alicante,ES)

Authors:
HMC Herminio Morillas Climent1 , JSM Julia Seller Moya1 , EGJ Emilio Galcera Jornet1 , EAT Edgardo Alania Torres1 , AVL Alvaro Vicedo Lopez1 , YRP Ydelise Rodriguez Pichardo1 , AL Ainhoa Larumbe1 , AVM Alfonso Valle Munoz1 , 1Denia Marina Salud Hospital - Alicante - Spain ,

Citation:

BACKGROUND: Sacubitril-Valsartan has improved the prognosis of patients with heart failure and reduced ejection fraction. Empaglifozin has reduced heart failure incidence in patients with type 2 diabetes. However, data regarding safety and tolerability of joint intake are scarce.
PURPOSE: The aim of our study is to describe clinical use of Sacubitril-Valsartan together with Empaglifozin coadministration in real world practice, with special focus on safety and tolerability.
METHODS: We performed a single-centre, retrospective evaluation of Sacubitril-Valsartan and Empaglifozin joint prescription from the date of the first drug prescription until the 20th December 2018. Inclusion criteria was any sustained prescription of both drugs by Cardiology and/or General Practitioners. Patients were excluded if no data were available or prescription had an incorrect indication.
We collected baseline characteristics of the patients, data of tolerance and information regarding laboratory markers. Statistical analysis was performed using SPSS Software for MAC, 20.0 version. Changes in cuantitative values over time were analyzed using T-Test. 
RESULTS: From the 3rd of March 2016 to the 20th of December 2018, 41 patients were included in the study. Three patients were excluded from the final analysis (1 due to unavailable data, 2 because of incorrect prescription of Sacubitril-Valsartan with LVEF > 45%).
Thirty-eight patients remained, of which 62% were men. Mean age was 68 years old. All the patients were diabetic, 67% hypertensive and 80% received statins. Ischaemic heart disease was the main cause of heart failure (65%). At baseline, 60% of the patients reported NYHA functional class II symptoms.
Sacubitril-Valsartan was started first in 14 patients, Empaglifozin in 11 patients, and both drugs were started at the same time in 13 patients, usually after heart failure admission.
During a medium follow-up of 432 +/- 202 days, only 4 patients (10,53%) were admitted to the hospital due to acute heart failure. No cardiovascular nor renal deaths were registered.
Creatinine (Cr) levels remained stable during follow-up, with a non-significant decrease of Cr values from 1,043mg/dl (SD = 0,33) at baseline to 1,034 mg/dl (SD = 0,29) at the end of the study. Blood test at intermediate time-points showed similar results (Cr = 1,068; 0,987, and 0,997mg/dl at blood test 2, 3 and 4 respectively). Cr increase above 40% of baseline levels was detected only in 3 patients (7,89%) and reversible in all, without any case of severe acute kidney injury.
Glycated hemoglobin (HbA1c) showed a mild and also non-significant reduction during the study, from 6,834% (SD = 1,19) at baseline to 6,723% (SD = 0,99) in the last visit. Glycemic values improved shortly after initiating Sacubitril-Valsartan or Empaglifozin (HbA1c 6,410 at blood test 2, p = 0,065).
CONCLUSIONS: Combination of Sacubitril-Valsartan and Empaglifozin is frequent, safe, and well tolerated in real world clinical practice.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are